Navigation Links
New BioTrends Report Explores Anticipated Treatment Pattern Shifts Expected with the Proposed Bundled Payment Structure Planned for 2011
Date:7/28/2009

EXTON, Pa., July 28 /PRNewswire/ -- BioTrends Research Group, Inc. recently released its baseline report assessing awareness of the Centers for Medicare and Medicaid Services (CMS) proposed dialysis bundled payment plan among Medical Directors and Renal Administrators in dialysis units across the country. Approximately half of the respondents were affiliated with large dialysis chains (i.e. Fresenius, DaVita, DCI) with the other half operating in small-to-medium sized dialysis chains, independent units, and hospital based units.

The report, based on survey responses from 160 Medical Directors and 117 Renal Administrators and supplemented with qualitative interviews conducted with key stakeholders (dialysis organization executives, renal organizations, key opinion leaders on the subject of bundling), examines awareness of the proposed bundle components, anticipated changes in practice management, the degree of control in decision making Medical Directors and Renal Administrators expect to have, and their overall concerns with bundle implementation. Specific impact on the utilization of ESAs, IV iron, Vitamin D, phosphate binders, and Amgen's Sensipar is explored as it relates to how likely various scenarios are and whether or not they are in the best interest of dialysis patients.

Although exact details of the bundled payment system have yet to be finalized and made official, Medical Directors and Renal Administrators are clearly concerned about the impact of these changes on the fiscal health (and viability) of their units as well as the potential impact on patient outcomes. The most valuable sources of information on bundling were noted as the Renal Physician's Association for Medical Directors and the ESRD Networks for Renal Administrators.

The full report is available for purchase at www.bio-trends.com. A follow up wave of this report is planned in early 2010 after additional details on the bundle legislation have been released.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
3. New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)
4. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
5. BioTrends Announces a New Syndicated Report Series, LaunchTrends(TM): Feraheme
6. Virginia Tech Report Has National Importance
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
9. Haemacure Reports Third Quarter 2007 Results
10. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
11. Biotech Finishes on a High in August, Burrill Report Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... Virginia (PRWEB) , ... December 08, 2016 , ... ... services company offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care ... operations and general counsel and Eric Hoessel to vice president of sales. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... 2016 Mitsubishi Tanabe Pharma Corporation (Head Office: ... CEO: Dr. Masayuki Mitsuka ) has presented data ... edaravone intravenously in 10-14 day cycles for 48 weeks ... ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented ... in Dublin, Ireland . ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
Breaking Medicine Technology: